Your browser doesn't support javascript.
loading
Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review.
Raouf, Sherif; Bertelli, Gianfilippo; Ograbek, Agnes; Field, Polly; Tran, Irwin.
Afiliação
  • Raouf S; Department of Oncology - Clinical, Queen's Hospital, Rom Valley Way, Romford, RM7 0AG, UK.
  • Bertelli G; Department of Oncology, Singleton Hospital, Sketty Lane, Swansea, SA2 8QA, UK.
  • Ograbek A; Global Product Development - Medical Affairs Oncology, Roche Products Limited, Hexagon Place, Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, UK.
  • Field P; Value Demonstration Practice, PharmaGenesis Oxford Central, 38 St Aldates, Chamberlain House, Oxford, OX1 1BN, UK.
  • Tran I; Global Access Department, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
Future Oncol ; 15(5): 543-561, 2019 Feb.
Article em En | MEDLINE | ID: mdl-30379088
ABSTRACT

AIM:

This review aims to assist physicians and payers in assessing the efficacy and safety of bevacizumab in real-world clinical practice by identifying evidence on the comparative effectiveness and safety of bevacizumab in its most frequent indications. Materials &

methods:

In a systematic review of the published literature, electronic databases (Embase®, MEDLINE® and the Cochrane Library) were searched in May 2016 and updated in January 2017; 20 scientific congresses were searched in 2014-2017.

RESULTS:

Of 61 included publications, 49, eight, four and 0 concerned metastatic colorectal cancer, metastatic breast cancer, advanced ovarian cancer and cervical cancer, respectively. Fifteen publications (metastatic colorectal cancer) reported on factors predictive of response to therapy.

CONCLUSION:

Effectiveness findings from real-world studies broadly supported results from registration studies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores da Angiogênese / Bevacizumab / Antineoplásicos Imunológicos / Neoplasias Tipo de estudo: Prognostic_studies / Systematic_reviews Limite: Female / Humans Idioma: En Revista: Future Oncol Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores da Angiogênese / Bevacizumab / Antineoplásicos Imunológicos / Neoplasias Tipo de estudo: Prognostic_studies / Systematic_reviews Limite: Female / Humans Idioma: En Revista: Future Oncol Ano de publicação: 2019 Tipo de documento: Article